吉格列汀酒石酸盐(Gemigliptin L-tartrate Sesquihydrate) - 药物靶点：DPP-4_在研适应症：2型糖尿病_专利_临床

概要

基本信息

药物类型

化学药

别名

Gemigliptin、Gemigliptin tartrate sesquihydrate、Gemiglo

+ [4]

靶点

DPP-4

作用机制

DPP-4抑制剂(二肽基肽酶IV抑制剂)

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病

非在研适应症

非胰岛素依赖型糖尿病2肝病

原研机构

LG Life Sciences Ltd.

在研机构

LG Life Sciences Ltd.

LG Chem Ltd.

非在研机构

华润双鹤药业股份有限公司

最高研发阶段批准上市

首次获批日期

韩国 (2012-06-27),

2型糖尿病

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构

分子式C44H56F16N10O19

InChIKeyWVZSXKFQIVMBIP-SQYFXPODSA-N

CAS号1375415-82-9

关联

38

项与吉格列汀酒石酸盐相关的临床试验

NCT04544319 / Unknown status临床1期

Clinical Trial to Compare the Pharmacokinetics, Safety and Tolerability of the FDC of Gemigliptin/Dapagliflozin 50/10 mg to Each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg

To identify bioequivalence between Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg to Each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg

开始日期2020-10-01

申办/合作机构

LG Chem Ltd.

NCT04255238 / Unknown status临床3期

A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group, Phase 3 Trial to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Compared to add-on Therapy With Gemigliptin 50 mg in Combination With Metformin or Dapagliflozin 10 mg in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

The objective of this study is to evaluate the efficacy and safety of dual add-on therapy with Gemigliptin 50 mg and Dapagliflozin 10 mg added to Metformin compared to add-on therapy with Gemigliptin 50 mg in combination with Metformin or Dapagliflozin 10 mg in combination with Metformin in patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin alone

开始日期2020-06-30

申办/合作机构

LG Chem Ltd.

NCT05663736 / Recruiting临床4期IIT

Comparison in Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes Uncontrolled With Metformin

Among DPP-4 inhibitors, gemigliptin is a relatively recently developed drug, and many clinical studies have shown results that are equivalent to or superior to existing DPP-4 inhibitors such as sitagliptin. However, studies on the safety of gemigliptin in cardiovascular disease have not been conducted, and studies on its effect on cardiac function are lacking. Considering the increase in hospitalizations due to heart failure found in some DPP-4 inhibitor studies, investigation of directly effect of gemigliptin on heart function would be clinically important.

开始日期2020-01-01

申办/合作机构

Seoul National University Bundang Hospital

100 项与吉格列汀酒石酸盐相关的临床结果

登录后查看更多信息

100 项与吉格列汀酒石酸盐相关的转化医学

登录后查看更多信息

100 项与吉格列汀酒石酸盐相关的专利（医药）

登录后查看更多信息

96

项与吉格列汀酒石酸盐相关的文献（医药）

2024-11-01·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Gemigliptin mitigates TGF-β-induced renal fibrosis through FGF21-mediated inhibition of the TGF-β/Smad3 signaling pathway

Article

作者: Byun, Jun-Kyu ; Jung, Gwon-Soo

Fibroblast growth factor 21 (FGF21), a well-known regulator of metabolic disorders, exhibits the potential to prevent renal fibrosis by negatively regulating the transforming growth factor β (TGF-β)/Smad3 signaling pathway. Gemigliptin and other dipeptidyl peptidase-4 inhibitors are frequently used for the management of patients with type 2 diabetes. However, the protective effect of gemigliptin against renal fibrosis, particularly its potential to upregulate the expression of FGF21, remains incompletely understood. This study assessed the renoprotective effects of gemigliptin against TGF-β-induced renal fibrosis by enhancing the expression of FGF21 in the cultured human proximal tubular epithelial cell line HK-2. Treatment with FGF21 effectively prevented TGF-β-induced renal fibrosis by attenuating the TGF-β/Smad3 signaling pathway. Similarly, gemigliptin exhibited protective effects against TGF-β-induced renal fibrosis by mitigating TGF-β/Smad3 signaling through the upregulation of FGF21 expression. However, the protective effects of gemigliptin were blocked when FGF21 expression was knocked down in TGF-β-treated HK-2 cells. These results indicate that gemegliptin has the potential to exhibit protective effects against TGF-β-induced renal fibrosis by elevating FGF21 expression levels in cultured human proximal tubular epithelial cells.

2024-09-01·DIABETES OBESITY & METABOLISM

Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study

Article

作者: Kim, Kyoung‐Ah ; Hwang, You‐Cheol ; Park, Cheol‐Young ; Won, Jong Chul ; Kang, Jun Goo ; Yoo, Hye Jin ; Park, Kyong Soo ; Chon, Suk ; Moon, Shin Je ; Cho, Ho Chan ; Kim, Tae Nyun ; Cho, Eunjoo ; Han, Kyung Ah ; Kim, Jeongyun ; Choi, Sung Hee

Abstract:

Aim:

To evaluate the efficacy and safety of gemigliptin and dapagliflozin dual add‐on therapy (GEMI + DAPA) to metformin in type 2 diabetes (T2D) patients who had inadequate glycaemic control on metformin alone, compared with a single add‐on of either gemigliptin (GEMI) or dapagliflozin (DAPA) to metformin.

Materials and Methods:

In this randomized, double‐blind, double‐dummy, active‐controlled, parallel‐group, phase 3 study, 469 T2D patients treated with a stable dose of metformin for 8 weeks or longer were randomized to receive GEMI + DAPA (n = 157) and either GEMI (n = 156) or DAPA (n = 156). The primary endpoint was change in HbA1c levels from baseline at week 24.

Results:

Baseline characteristics including body mass index and T2D duration were similar among groups. At week 24, the least square mean changes in HbA1c from baseline were −1.34% with GEMI + DAPA, −0.90% with GEMI (difference between GEMI + DAPA vs. GEMI −0.44% [95% confidence interval {CI}: −0.58% to −0.31%], P < .01) and −0.78% with DAPA (difference between GEMI + DAPA vs. DAPA −0.56% [95% CI: −0.69% to −0.42%], P < .01). Both upper CIs were less than 0, demonstrating the superiority of GEMI + DAPA for lowering HbA1c. The rates of responders achieving HbA1c less than 7% and less than 6.5% were greater with GEMI + DAPA (84.9%, 56.6%) than with GEMI (55.3%, 32.2%) and DAPA (49.3%, 15.3%). The incidence rate of adverse events was similar across groups, with low incidence rates of hypoglycaemia, urinary tract infection and genital infection.

Conclusions:

These results suggest that the addition of GEMI + DAPA to metformin as triple combination therapy was effective, safe and well‐tolerated, especially for T2D patients who experienced poor glycaemic control on metformin alone.

2024-07-01·Biochemistry and biophysics reports

Gemigliptin, a potent selective dipeptidyl peptidase 4 inhibitor, protects endothelial progenitor cells by oxidative stress via caspase-3 dependent pathway

Article

作者: Lee, Mijung ; Kim, Manho ; Tariq, Amna Rashid

Endothelial progenitor cells (EPCs) are exclusive players in vasculogenesis and endothelial regeneration. EPCs are of two types and their differentiation is mediated by different growth factors. A decrease in EPC number and function causes cardiovascular abnormalities and reduced angiogenesis. Various studies has documented a role of EPCs in diabetes. EPCs treatment with different drugs improve insulin secretion but causes other abnormalities. In vivo and in vitro studies have reported anti glycation effect of gemigliptin but no data is available on in vitro effect of gemigliptin on EPC number and functional credibility. The current study was aimed to find an in vitro effect of gemigliptin on EPC number and function along with an effective treatment dose of gemigliptin. EPCs were isolated, cultured and phenotypically characterized using Dil- AcLDL and ulex-lectin fluorescence staining. EPCs were then treated with different doses of Zemiglo and their viability analyzed with viability assay using water-soluble tetrazolium salt (WST-1), by Annexin V and Propidium Iodide (PI) staining, senescence-associated beta-galactosidase (SA-β-gal) staining, western blot and Flow cytometric analysis of apoptotic signals. The results demonstrated that the isolated EPCs has typical endothelial phenotypes. And these EPCs were of two types based on morphology i.e., early and late EPCs. Gemigliptin dose dependently improved the EPCs morphology and increased EPCs viability, the most effective dose being the 20 μM. Gemigliptin at 10 μM, 20 μM and 50 μM significantly increased the BCL-2 levels and at 20 μM significantly decreased the Caspase-3 levels in EPCs. In conclusion, gemigliptin dose dependently effects the EPCs viability and morphology through Caspase-3 signaling. Our results are the first report of gemigliptin effect on EPC viability and morphology.

4

项与吉格列汀酒石酸盐相关的新闻（医药）

2023-02-28

·PRNewswire

M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavoglifozin) for Brazil and Mexico

MEXICO CITY, Feb. 28, 2023 /PRNewswire/ -- M8 Pharmaceuticals and Daewoong Pharmaceuticals announced they have signed an exclusive licensing agreement whereby M8 will have the rights to register and commercialize Envlo™ (Enavoglifozin) for Brazil and Mexico. The novel drug Envlo™ (Enavoglifozin) is a SGLT2 (sodium glucose cotransporter 2) inhibitor type diabetes treatment, and last November, it has received a regulatory approval in South Korea. Phase 3 clinical trials have been performed on type 2 diabetes patients and its results demonstrated excellent effects in dropping blood sugar level drop. The safety of Envlo™ has been confirmed and proven to show equal medicinal effect with only 0.3mg, which is 1/30 of the amount of existing SGLT2 inhibitor and has been shown to be a promising new treatment option for patients and prescribers who were unsatisfied with the blood sugar controls. It has been proven to be efficacious as a monotherapy, metformin combined modality therapy and metformin and gemigliptin or other DDP4 (Inhibitors of dipeptidyl peptidase 4) combined modality therapy. During the development of the product, Envlo™ was designated as South Korea's first drug to received a fast-track review in 2020, and is expected to be launched in South Korea by Daewoong in the first half of 2023. The Enavogliflozin monotherapy trial was a placebo-controlled superiority study. The HbA1c decreased in the Enavogliflozin group by approximately 1% over the placebo group, which was statistically significant. In addition, significant improvements were confirmed in weight, blood pressure, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) compared to the placebo group. The two combination trials, Enavogliflozin-Metformin and Enavogliflozin-Metformin-Gemigliptin combination, demonstrated non-inferiority in HbAc1 change compared to dapagliflozin 10 mg and its equivalent combinations. Through this agreement, Daewoong Pharmaceuticals has the plan to accelerate further overseas expansion for Enavogliflozin including China, Saudi Arabia and Russia and expand into 15 countries by 2025 and 50 countries by 2030. M8 Pharmaceuticals continues its commitment of bringing proven and innovative products to Latin American patients, and the agreement reinforces its commitment and capabilities in the area of cardiometabolism. Diabetes affects over 30 million people in Brazil and Mexico, and many of these patients continue to need better therapeutic options to optimize symptom control and improve their quality of live. According to IQVIA, the SGLT2 inhibitor market in Brazil and Mexico exceeds the 470 million USD in value and grows at a rate of more than 20% annually. "We are delighted to continue to strengthen our strategic partnership with Daewoong and see a large opportunity to address the unmet needs of millions of Latin Americans suffering from diabetes, by bringing a product like Envlo™ to the SGLT2 market with the potential to be best-in-class" stated Joel Barlan, M8's CEO. CEO Seng-ho Jeon from Daewoong Pharmaceutical stated "This contract with M8 is an example proving that Daewoong Pharmaceutical's synthetic new drugs such as Fexuclue and Envlo, are recognized as global blockbusters" and "With this contract in Central and South America as the starting point, we expect that the 36th domestically produced new drug Envlo will expand its entry into the global market in the future." About M8 PHARMACEUTICALS M8 is a specialty biopharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in Latin America: Brazil and Mexico. We aim to become the preferred pharmaceutical partner for the licensing of high-value innovative and proven therapies across our main therapeutic areas CNS, Respiratory, Cardiometabolic, Immunology, Gastroenterology, Onco-hematology and Rare Diseases. Our mission is to provide the people of Latin America with access to the proven and innovative medicines they need to transform their lives. For further information, please visit: For more information please contact: Joel Barlan Chief Executive Officer T: +52 (55) 4431 2933 [email protected] Rafael Ferrer Vice President of Corporate Development & Strategy T: +1 (305) 299 6998 [email protected] SOURCE M8 Pharmaceuticals

临床3期引进/卖出临床结果快速通道

2022-12-15

·FierceBiotech

Innovent plucks Chinese rights to LG Chem's gout disease treatment in nearly $100M deal

LG Chem's deal with Innovent comes months after the Korea-based company bought Aveo Oncology. Innovent is adding a new late-stage med to its pipeline, buying the Chinese rights to LG Chem’s phase 3 gout disease treatment for nearly $100 million. The agreement, announced Thursday, gives Innovent exclusive Chinese rights to tigulixostat, a non-purine xanthine oxidase inhibitor that manages the buildup of uric acid in patients with gout. In return, the company is paying LG Chem $10 million upfront with $85.5 million in biobucks waiting in the wings. Tigulixostat lands in Innovent’s lap with the wind in its sails after beating out both placebo and Takeda’s Uloric in uric acid reductions during a phase 2 study. LG Chem launched a phase 3 trial this quarter with the expectation of recruiting 3,000 patients across the U.S., Europe and other countries. The approval potential of the med is particularly tantalizing to Innovent given that the prevalence of hyperuricemia in China could be as high as 13.3% of the population. Another study conducted by China’s CDC found that the prevalence among adults is 11.1%. The med slides into a portfolio that includes eight approved meds in China, primarily in oncology, but a relatively thin slate of metabolic treatments. As for LG Chem, the rights handoff continues a string of deals after agreeing to buy Aveo Oncology and its approved kidney cancer drug in October for $566 million. The company noted that one of the benefits to partnering with Innovent was getting a foot in the door to the Chinese market. LG Chem’s only approved med is Zemiglo, a Type 2 diabetes treatment greenlighted for use in Korea and Thailand. Beyond tigulixostat, the company is working on treatments for nonalcoholic steatohepatitis, obesity and Type 1 diabetes.

临床3期引进/卖出上市批准临床2期并购

2022-12-06

·BioSpace

Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

Delivers new drug for two consecutive years by obtaining product license on "Envlo", Korea's 36th new drug from the Ministry of Food and Drug Safety Plans to enter the type 2 diabetes global market worth $71.4 billion Provides new and broad treatment options for patients with insufficient blood glucose control with three indications SEOUL, South Korea, Dec. 6, 2022 /PRNewswire/ -- Daewoong Pharmaceutical Co., Ltd. (CEO Jeon Sengho, Lee Changjae), a global healthcare company, announced on 5th that its "Envlo 0.3mg", a new sodium-glucose cotransporters 2 inhibitor (SGLT2) developed to treat type 2 diabetes mellitus obtained a product license from the Ministry of Food and Drug Safety on November 30. Envlo is indicated for monotherapy, combination therapy with Metformin and combination therapy with Metformin and Gemigliptin. SGLT2 inhibitors, which are rapidly replacing the global type 2 diabetes market worth $71.4 billion, are known to account for about $20.7 billion globally and $100 million in Korea as of 2021. Until now, the development and approval of SGLT2 inhibitors have been carried out mainly by multinational pharmaceutical companies. Daewoong Pharmaceutical, South Korea's leading healthcare company, became the first domestically to succeed in developing a new antidiabetic drug in this class by obtaining a product license. Daewoong Pharmaceutical plans to actively pursue the global market through this product. Daewoong Pharmaceutical plans to move quickly with the procedures concerning Envlo's insurance coverage and price in order to register the drug in National Health Insurance System with an indication of monotherapy, combination therapy with Metformin or Metformin & Gemigliptin in the first half of 2023. At the same time, the company has developed a roadmap to enter the global market over 10 countries including China, Brazil and Saudi Arabia by 2025 and 50 countries by 2030. The company is also running clinical trials for indication expansion while developing combination drugs. Daewoong Pharmaceutical aims to deliver the metformin combination drug in the second half of 2023, by accelerating the trial. The company estimates to achieve a cumulative three-year sale of 100 billion Korean Won. Earlier in October, Daewoong Pharmaceutical announced the Phase 3 study results of Envlo in patients with type 2 diabetes which have shown excellent hypoglycemic effect and the safety. In particular, Envlo has demonstrated its equivalent efficacy with 0.3 mg, which is less than one-thirtieth dosage of existing SGLT2 inhibitors. Its indication is also expected to provide a new treatment option for patients with insufficient blood sugar control. An official from Daewoong Pharmaceutical said, "While SGLT2 inhibitors are drawing the most attention in the global market, it is meaningful that we are the first company in Korea to develop the new diabetes medication in this class." The company official also added, "We will make our best effort to improve the quality of life of patients by providing the best-in-class antidiabetic drug. We will also contribute to the development of global pharmaceutical industry by continuously strengthening new drug development and global business through open collaboration with various partners." Meanwhile, Envlo, approved as the 36th new drug in Korea following the 34th new drug "Fexuclue" last year, listed its name as a first domestic drug to be designated for an accelerated approval by the Ministry of Food and Drug Safety in 2020. Company Codes: Korea:069620

临床3期上市批准临床结果

100 项与吉格列汀酒石酸盐相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	吉格列汀酒石酸盐	A10BH06	DB12412

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	韩国	LG Life Sciences Ltd.	2012-06-27
2型糖尿病	韩国	LG Chem Ltd.	2012-06-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非胰岛素依赖型糖尿病2	临床3期	-	LG Life Sciences Ltd.	2016-10-17
糖尿病	临床1期	-	LG Chem Ltd.	2019-11-01
肝病	临床1期	德国	LG Life Sciences Ltd.	2013-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SOLUTION 2 Study (ADA2023)	N/A	追加	469	Gemigliptin and Dapagliflozin	蓋憲構齋壓窪壓鏇鏇鏇(鬱襯網鹹獵憲繭窪製憲) = 積鬱鹹鑰壓齋淵廠繭積襯遞憲憲廠壓願選積襯 (醖製鹽廠顧鏇築壓醖廠 )	积极	2023-06-20
				Gemigliptin	蓋憲構齋壓窪壓鏇鏇鏇(鬱襯網鹹獵憲繭窪製憲) = 衊鏇鹽積願範鬱壓製廠襯遞憲憲廠壓願選積襯 (醖製鹽廠顧鏇築壓醖廠 )
NCT05663736 (Pubmed)	临床4期	2型糖尿病	-	Gemigliptin	糧選獵壓糧築獵構餘觸(獵繭構鹽夢簾構餘積遞) = Gemigliptin induced favorable changes in body composition 壓築醖糧淵鏇積衊蓋觸 (鏇積構觸夢醖簾糧蓋襯 )	-	2023-04-12
				Glimepiride
FC 092 (ERA2021)	N/A	糖尿病肾病 hemoglobinA1C \| serum bone alkaline phosphatase \| urine neutrophil gelatinase-associated lipocalin (NGAL)/Cr ... 更多	201	Gemigliptin 50 mg	蓋齋齋構範襯鹽選選觸(觸鏇獵網願範齋簾網夢) = 膚獵鬱願窪膚蓋膚憲鬱齋窪遞獵鑰醖鑰憲觸衊 (齋鑰窪憲膚遞鹽憲鬱範 )	积极	2021-05-29
				Placebo	蓋齋齋構範襯鹽選選觸(觸鏇獵網願範齋簾網夢) = 膚糧鑰壓願憲遞艱網選齋窪遞獵鑰醖鑰憲觸衊 (齋鑰窪憲膚遞鹽憲鬱範 )
NCT02290301 (OPTIMUS, Pubmed \| Sci Rep)	N/A	2型糖尿病	5,179	Gemigliptin	獵餘蓋積願襯廠壓繭獵(糧夢夢鏇簾壓壓顧鑰顧) = 顧簾醖膚鑰選網願構願醖遞鑰範鬱膚壓製醖鏇 (願鹹製襯遞衊窪鑰獵選 ) 更多	-	2020-11-04
NCT02831361 (ZEUS II, Pubmed) 人工标引	临床3期	2型糖尿病	283	gemigliptin	壓餘餘廠選遞構憲觸鏇(鹽選淵艱鑰醖鹽壓繭鬱): difference = -0.7 (95% CI, -0.9 ~ -0.4), P-Value = <0.0001 更多	积极	2020-01-01
				Placebo
NCT01990469 (TROICA, Pubmed \| Diabetes Obes Metab) 人工标引	临床3期	2型糖尿病	219	gemigliptin	願構願齋鹽選齋築網簾(觸鑰蓋襯壓築獵蓋醖顧) = 淵鹹糧鏇糧積製夢襯選觸鏇醖艱願顧淵構繭積 (壓艱廠積獵簾繭壓鑰鑰 ) 更多	积极	2017-05-01
				Placebo	願構願齋鹽選齋築網簾(觸鑰蓋襯壓築獵蓋醖顧) = 窪觸選積蓋夢餘簾鏇廠觸鏇醖艱願顧淵構繭積 (壓艱廠積獵簾繭壓鑰鑰 ) 更多
ASN2016	N/A	阿霉素的毒性 DPP-IV \| GLP-1 \| Bax/Bcl-2 ratio ... 更多	-	Adriamycin	夢淵齋鬱顧膚鹹鹽醖艱(醖憲選襯鏇積鏇願繭夢) = 鹽構選夢餘夢糧窪廠齋積顧築選艱餘築蓋衊製 (餘範衊構膚範製糧築鏇 ) 更多	积极	2016-11-15
				Adriamycin+Gemigliptin	夢淵齋鬱顧膚鹹鹽醖艱(醖憲選襯鏇積鏇願繭夢) = 製獵鹹憲鑰顧築築鏇鬱積顧築選艱餘築蓋衊製 (餘範衊構膚範製糧築鏇 ) 更多
NCT01990469 (EASD2016)	临床3期	2型糖尿病追加	-	Gemigliptin 50 mg q.d	築繭憲繭顧網糧簾窪鹽(願鹹觸獵鑰壓網積鬱製) = 窪獵夢積顧遞廠蓋憲築齋積壓願夢鏇顧膚鏇餘 (遞鏇獵蓋淵鬱鑰夢鑰壓, 0.17)	积极	2016-09-13
				Placebo	築繭憲繭顧網糧簾窪鹽(願鹹觸獵鑰壓網積鬱製) = 憲膚製餘獵蓋襯網鑰鬱齋積壓願夢鏇顧膚鏇餘 (遞鏇獵蓋淵鬱鑰夢鑰壓, 0.18)
NCT01968044 (GUARD study, EASD2016)	临床3期	2型糖尿病 eGFR	-	Gemigliptin	餘艱廠獵齋憲選獵廠廠(構淵廠餘選選膚鏇範願) = 醖製夢簾壓憲鬱窪鏇襯糧鏇醖廠構鑰簾齋壓觸 (鬱餘餘積糧繭夢鹹積鏇, 0.14) 更多	积极	2016-09-13
				Placebo	餘艱廠獵齋憲選獵廠廠(構淵廠餘選選膚鏇範願) = 觸築鹽廠構鏇窪選衊壓糧鏇醖廠構鑰簾齋壓觸 (鬱餘餘積糧繭夢鹹積鏇, 0.14)
NCT01787396 (EASD2015)	临床3期	2型糖尿病	69	Gemigliptin 50 mg	獵艱鹹積齋鑰觸願糧獵(鹽餘獵願鏇繭積蓋範鏇) = reported more frequently in glimepiride group than in other groups 艱鬱遞憲艱繭獵遞醖襯 (範鹹築窪憲鹽鏇顧繭範 )	积极	2015-09-17
				Sitagliptin 100 mg